clinical trial · NCT07423546
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
New York State Psychiatric Institute·phase2·not yet recruiting·n = 12
SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve DisorderXanomeline and trospium chloride (KarXT)
brief summary
This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by \[18F\]DOPA Kicer (\[18F\]DOPA relative uptake rate)).
started
Jul 1, 2026
primary completion
Apr 30, 2027
completion
Dec 31, 2027
last updated
Apr 13, 2026
official title
A Multimodal PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol